Objective To evaluate the efficacy of artificial liver support system (ALSS) in the treatment of virus liver failure patients in a large controlled clinic trial. Methods Nine hundred and two patients with virus liver failure enrolled were divided into an ALSS treatment group of 507 and a control group of 395 without ALSS treatment. The analysis of survival time was computed by the Kaplain-Maier method, and comparison among groups was done by Log-Rank and Breslow test. Results ALSS affected the survival time of acute and subacute virus liver failure patients and prolonged their survival time significantly. ALSS also prolonged the survival time of B liver failure patients and affected the short-term survival time of E liver failure patients. The number of times of ALSS effected on the survival time of liver patients obviously. Conclusions Multi-ALSS treatment prolongs the survival time of acute and subacute virus liver failure patients and is more effective than the standard medicinal liver care treatment. The treatment with ALSS for the liver failure patients is important and necessary.